Reata Pharmaceuticals Inc. (NASDAQ:RETA) posted its quarterly earnings results on Monday. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10. The company earned $12.55 million during the quarter, compared to analysts’ expectations of $12.46 million.

Reata Pharmaceuticals (NASDAQ:RETA) opened at 36.11 on Tuesday. The stock’s market cap is $806.16 million. Reata Pharmaceuticals has a 12 month low of $11.03 and a 12 month high of $41.60. The firm has a 50-day moving average price of $25.57 and a 200-day moving average price of $21.28.

In other news, Director R Kent Mcgaughy, Jr. purchased 308,220 shares of the company’s stock in a transaction dated Thursday, August 18th. The shares were acquired at an average price of $17.08 per share, with a total value of $5,264,397.60. Following the transaction, the director now owns 25,004 shares of the company’s stock, valued at $427,068.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Jack Nielsen purchased 1,780 shares of the company’s stock in a transaction dated Monday, August 22nd. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $30,260.00. Following the transaction, the director now directly owns 1,780 shares in the company, valued at approximately $30,260. The disclosure for this purchase can be found here. 62.40% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System increased its position in Reata Pharmaceuticals by 0.8% in the third quarter. California State Teachers Retirement System now owns 12,025 shares of the company’s stock worth $317,000 after buying an additional 100 shares during the last quarter. Bank of New York Mellon Corp increased its position in Reata Pharmaceuticals by 41.9% in the third quarter. Bank of New York Mellon Corp now owns 15,570 shares of the company’s stock worth $410,000 after buying an additional 4,599 shares during the last quarter. Morgan Stanley increased its position in Reata Pharmaceuticals by 121.6% in the third quarter. Morgan Stanley now owns 15,610 shares of the company’s stock worth $411,000 after buying an additional 8,567 shares during the last quarter. Northern Trust Corp increased its position in Reata Pharmaceuticals by 19.8% in the third quarter. Northern Trust Corp now owns 61,879 shares of the company’s stock worth $1,632,000 after buying an additional 10,239 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. increased its position in Reata Pharmaceuticals by 77.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 95,109 shares of the company’s stock worth $2,507,000 after buying an additional 41,480 shares during the last quarter. 71.23% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have recently issued reports on RETA shares. Zacks Investment Research raised Reata Pharmaceuticals from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a research report on Wednesday, September 21st. Piper Jaffray Cos. set a $33.00 price target on Reata Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, October 7th.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

5 Day Chart for NASDAQ:RETA

Receive News & Stock Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.